Acute rejection is associated with long-term effects. Previous studies have suggested that the occurrence of acute rejection and increasing frequency of acute rejection results in decreased long-term renal allograft survival among kidney transplant patients. [2] [3] [4] Routine monitoring of kidney function includes monitoring for an increase in detected after substantial damage has occurred. 5 Detection of subclinical rejection (SCR) can give providers the opportunity to intervene earlier before the presence of histological changes specific for acute rejection on screening or protocol biopsy, in the absence of clinical symptoms or signs. 6 However, blood-based gene markers for kidney rejection may occur before histologic abnormalities are found through biopsy and offer an opportunity for earlier intervention and adjustment to immunosuppressive regimens.
The Kidney Solid Organ Response Test (kSORT) assay is a 17-gene set non-invasive molecular assay that measures blood-based gene markers for transplanted kidney rejection. In the recently published Acute Rejection in Renal Transplantation (AART) study, acute rejection was detected by kSORT up to 3 months before detection by biopsy 7 , giving providers an earlier opportunity to modify immunosuppression to prevent subsequent rejection. Previous data have shown that more frequent monitoring for SCR results in 8 The objective of this exploratory analysis is to evaluate the potential budget impact of the kSORT assay from a commercial payer perspective.
Methods /
kSORT assay as a monitoring tool for patients who have undergone a renal transplant. The model projects the impact of adoption of this product over the course of two years. It considers costs associated with the kSORT assay in relation to the cost impact of improved detection, development of alternative strategies, and subsequent management of subclinical rejection (SCR). The model was built as an interactive spreadsheet using Microsoft Excel 2010.
Clinical and economic inputs and assumptions were based on information from the peer-reviewed and publicly available literature (see references) across a number of clinical scenarios. When published sources were not available, data and assumptions were based on the consensus of a multidisciplinary panel of experts. See Tables 1 and 2 for inputs around costs and probabilities. 2. As a starting point, the base case scenario assumes equal diagnostic performance of PB and the kSORT-a conservative assumption.
3. Diagnosis of SCR results in a change in management by physicians to optimize drug regimens, thereby modifying the effect of SCR on acute clinical rejection (ACR) and graft failure (GF).
It is assumed that a diagnosis of SCR results in a 90 percent reduction in ACR.
5. Diagnosis of SCR results in a 50% reduction in GF, independent of ACR.
6. The model includes the costs of the tests, per their indications for use, only before ACR or GF has occurred.
7. The prevalence of acute SCR decreases through time 9 , and assumes that prevalence of SCR is between approximately 15 to 30 percent. 10 8. Active SCR results in an increase in the risk of ACR (probabilities are calibrated in model). 10 9. The development of SCR and ACR (given SCR) are both time-dependent, and are associated with decreased probabilities as time passes.
10. The kSORT assay was assumed to be performed for incident kidney transplant patients during months 1, 3, 6, 9, 12, 18 and 24 post-procedure, while PB was assumed to take place during months 3 and 9.
Cohort Size
The size of the commercial plan is assumed to be 5 million, with a mix of 78% of adult and 22% pediatric (obtained through the Current Population Survey in 2013 11 ). The incidence of kidney transplant was estimated to be 70.3 per million for adults and 10.3 per million in the pediatric population (taken from the SRTR/OPTN 2012 report 1 , and adjusted using U.S. Census Data). For a plan of 5 million ansplants incorporating the aforementioned incidence data was estimated to be 285 patients.
Model Structure
A 2-year exploratory semi-Markov cohort model with monthly cycles was constructed to model the relationship between SCR, ACR, and GF. Four separate Markov models were created, each representing one of the four scenarios described above, while incorporating the months during which a patient receives the respective monitoring tool (i.e., kSORT, PB, or both).
Patients enter the model in the "No SCR" health state, and can either develop SCR or GF. Patients who are in the SCR health state can enter a "post-SCR" state where they no longer have active SCR, or they can experience ACR and enter a post-acute rejection state (PARS), after which patients may continue in that state or progress to GF (See Figure 1a) . Patients may enter the death state at any time from any health state. For patients who have kSORT and/or PB monitoring, patients may transition from the "No SCR health state and instead may transition to a "Detected SCR" health state (See Figure 1b) , progression to these health states.
Transition Probabilities
Detailed data on transition probabilities, especially those related to SCR, were not available for this patient population. As such, data were calibrated to approximate actual rates of ACR and GF, obtained from the SRTR/OPTN registry data 1 , while ensuring that modelled rates of SCR were within the range of prevalence data obtained from the literature. Transition probabilities are presented in Table 1 , while comparisons between the modelled and actual acute rejection and graft failure rates are shown in 
Results /
In the base case scenario, kSORT is expected to produce a minimal budget impact of $0.0057 PMPM in Table 3 . Total costs for the plan during Year 1 and Year 2 are provided in Figure 3 . 
MONITORING APPROACH BEFORE KSORT COVERAGE AFTER KSORT COVERAGE
Routine monitoring 60% 50%
PB only 40% 30%
kSORT only --10%
PB + kSORT --10% 
Sensitivity Analysis
Because of the small number of individuals in the plan with kidney transplant, the overall budget impact e model was most sensitive to kSORT costs (Figure 4 ). 
Conclusion /
This exploratory model indicates that the kSORT monitoring assay is expected to produce minimal in AR or GF. The low budget impact is attributed to the small patient population within plans with renal transplants every year, in addition to relatively low acute rejection and graft failure rates. Although the budget impact is small, additional clinical data showing how kSORT improves patient outcomes are needed. Long-term data may be of particular import in showing true value of the technology.
